DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

688192

CNE1000055W8

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
44.39 ^CNY	+3.26%		+25.40%	-7.23%

Apr. 24	Dizal Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer	CI
Apr. 07	U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations	CI

Dizal Pharmaceutical Co., Ltd.(XSSC:688192) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Dizal (Jiangsu) Pharmaceutical Co., Ltd.(XSSC:688192) added to S&P Global BMI Index

Latest news about Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Dizal Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer	Apr. 24	CI
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations	Apr. 07	CI
Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine	Dec. 13	CI
Dizal Pharmaceutical Co., Ltd.(SHSE:688192) added to Shanghai Stock Exchange Health Care Sector Index	Dec. 11	CI
Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH	Dec. 10	CI
Dizal Pharma to Invest 700 Million Yuan in New Dermatology Venture	Nov. 22	MT
Dizal Pharma Presents Positive Results of Lung Cancer Drug	23-10-24	MT
Dizal Announces Latest Research Findings on the Efficacy and Safety of Sunvozertinib in Treatment-Naive Patients	23-10-23	CI
Chinese Drug Regulator Puts Dizal Pharma's Lymphoma Drug in Priority Review	23-09-22	MT
Dizal Pharmaceutical Receives Priority Review by China NMPA for the Treatment of r/r PTCL	23-09-21	CI
Dizal Pharmaceutical Co., Ltd.(XSSC:688192) added to S&P Global BMI Index	23-09-18	CI
Dizal Pharmaceutical Co., Ltd. Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL	23-09-14	CI
Dizal (Jiangsu) Pharmaceutical's Anti-Lymphoma Medication Research Results Published in European Oncology Journal	23-09-11	MT
Dizal Pharmaceutical Announces Clinical Results of Golidocitinib Published in Annals of Oncology	23-09-10	CI
Anova Enterprises, Inc. Partners with Dizal Pharmaceuticals to Accelerate Development of DZD9008 for Patients with Advanced or Metastatic NSCLC with EGFR Exon20 Insertion Mutation	23-09-06	CI
Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Dizal's Sunvozertinib Approves by China NMPA with Potential for Best-In-Class Therapy in NSCLC with EGFR Exon20ins Mutations	23-08-23	CI
Dizal Will Present the Results of Molecular Analysis on EGFR Exon20ins Mutations in Tumor Tissue and Plasma ctDNA	23-08-17	CI
Dizal Pharma Gets European Regulator's Nod to Hold Tumor Drug Trial	23-06-13	MT
Dizal Pharmaceutical Co., Ltd. Presents Compelling Data of Its Robust Oncology Portfolio At the 2023 American Society of Clinical Oncology Annual Meeting	23-06-07	CI
Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Dizal Pharmaceutical Co., Ltd. announced that it expects to receive CNY 2.6081 billion in funding	23-03-23	CI
Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Dizal Pharma's Lung Cancer Drug Added to China's Priority Review List	23-01-17	MT

Chart Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Duration

Period

Chart Dizal (Jiangsu) Pharmaceutical Co., Ltd.

More charts

Dizal Jiangsu Pharmaceutical Co Ltd is a China-based company mainly engaged in the exploration, research, development and commercialization of innovative biomedicine. The Company focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The Company is still in the R&D stage.

Sector

Biotechnology & Medical Research

Calendar

2024-04-29 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

44.39 CNY

Average target price

52.16 CNY

Spread / Average Target

+17.49%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.	-7.23%	2.55B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Equities

688192

CNE1000055W8

Biotechnology & Medical Research

Dizal Pharmaceutical Co., Ltd.(XSSC:688192) added to S&P Global BMI Index

Latest news about Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Chart Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs